Definium Therapeutics, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Definium announced positive topline results from Panorama, a Phase 3 study of DT120 ODT (lysergide) in generalized anxiety disorder (GAD) enrolling 245 participants (96 receiving DT120 100µg, 97 placebo, 52 receiving DT120 50µg control). The primary endpoint was met: DT120 100µg achieved a placebo-adjusted HAM-A improvement of 5.1 points at Week 12 (p≤0.0001, Cohen's d=0.64); all key secondary endpoints were also met. This is Definium's second positive Phase 3 trial in GAD (following Voyage in August) and third positive Phase 3 readout overall (Emerge in MDD in June). The company plans a pre-NDA meeting in 4Q 2026 and NDA filing in 1H 2027.
Why this rating
Third consecutive positive Phase 3 readout significantly de-risks regulatory pathway for $488M market-cap company; NDA filing 6 months away supports near-term catalyst, but pre-clinical controlled substance represents material execution/regulatory risk.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $45.20 ▲ 5.83% | at our read · unknown $42.71 | +10 min · unknown $42.00 ▼ 1.66% | +30 min · unknown $41.07 ▼ 3.84% | +1 hr · unknown $40.85 ▼ 4.35% | +4 hrs · unknown $40.48 ▼ 5.21% |
The stock had already moved -5.51% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.